Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.

Auteurs

Dixon BP, Kavanagh D, Aris ADM, Adams B, Kang HG, Wang E, Garlo K, Ogawa M, Amancha P, Chakravarty S, Heyne N, Kim SH, Cataland S, Yoon SS, Miyakawa Y, Luque Y, Muff-Luett M, Tanaka K, Greenbaum LA

  • Date de publication

    August 2024

  • Type

    Article

  • Review

    Kidney Med

  • Researcher's name

    ADAMS Brigitte

  • Hôpital

    Hôpital Universitaire des Enfants

  • Service

    Néphrologie, Transplantation et Dialyse pédiatrique

  • PMID

    39105067

  • DOI

    10.1016/j.xkme.2024.100855